Mary E. Sayler

1.1k total citations
26 papers, 834 citations indexed

About

Mary E. Sayler is a scholar working on Pharmacology, Experimental and Cognitive Psychology and Psychiatry and Mental health. According to data from OpenAlex, Mary E. Sayler has authored 26 papers receiving a total of 834 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pharmacology, 16 papers in Experimental and Cognitive Psychology and 12 papers in Psychiatry and Mental health. Recurrent topics in Mary E. Sayler's work include Treatment of Major Depression (19 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (12 papers) and Attention Deficit Hyperactivity Disorder (8 papers). Mary E. Sayler is often cited by papers focused on Treatment of Major Depression (19 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (12 papers) and Attention Deficit Hyperactivity Disorder (8 papers). Mary E. Sayler collaborates with scholars based in United States. Mary E. Sayler's co-authors include Charles M. Beasley, Janet H. Potvin, Gary D. Tollefson, J C Bosomworth, Daniel N. Masica, Alvin H. Rampey, Bruce E. Dornseif, Denis Murphy, Anupam Pande and Arindam Pande and has published in prestigious journals such as Biological Psychiatry, Journal of Affective Disorders and Schizophrenia Research.

In The Last Decade

Mary E. Sayler

25 papers receiving 763 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary E. Sayler United States 13 561 385 300 239 96 26 834
J C Bosomworth United States 9 457 0.8× 324 0.8× 166 0.6× 184 0.8× 94 1.0× 10 713
Ward T. Smith United States 13 419 0.7× 298 0.8× 412 1.4× 203 0.8× 169 1.8× 17 892
William F. Boyer United States 16 432 0.8× 360 0.9× 300 1.0× 192 0.8× 227 2.4× 27 1.0k
Jay B. Cohn United States 17 554 1.0× 481 1.2× 417 1.4× 220 0.9× 151 1.6× 30 1.2k
Charles S. Wilcox United States 16 320 0.6× 275 0.7× 272 0.9× 171 0.7× 127 1.3× 27 806
J.D. Guelfi France 17 353 0.6× 506 1.3× 206 0.7× 473 2.0× 147 1.5× 55 1.1k
M. Fava United States 11 366 0.7× 351 0.9× 215 0.7× 263 1.1× 76 0.8× 12 1.0k
Ole Lemming Denmark 16 486 0.9× 464 1.2× 342 1.1× 301 1.3× 124 1.3× 27 1.1k
E Tricamo United States 19 776 1.4× 612 1.6× 420 1.4× 256 1.1× 137 1.4× 30 1.3k
Joseph Deltito United States 20 224 0.4× 408 1.1× 351 1.2× 347 1.5× 94 1.0× 34 962

Countries citing papers authored by Mary E. Sayler

Since Specialization
Citations

This map shows the geographic impact of Mary E. Sayler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary E. Sayler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary E. Sayler more than expected).

Fields of papers citing papers by Mary E. Sayler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary E. Sayler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary E. Sayler. The network helps show where Mary E. Sayler may publish in the future.

Co-authorship network of co-authors of Mary E. Sayler

This figure shows the co-authorship network connecting the top 25 collaborators of Mary E. Sayler. A scholar is included among the top collaborators of Mary E. Sayler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary E. Sayler. Mary E. Sayler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smith, Ward T., et al.. (1999). Pilot Study of Zatosetron (LY277359) Maleate, a 5-Hydroxytryptamine-3 Antagonist, in the Treatment of Anxiety. Journal of Clinical Psychopharmacology. 19(2). 125–131. 10 indexed citations
2.
Fava, M., et al.. (1998). 342. Fluoxetine versus sertraline and paroxetine in major depression: Safety and efficacy in anxious and nonanxious subgroups. Biological Psychiatry. 43(8). S103–S103. 1 indexed citations
3.
Fava, Maurizio, et al.. (1998). Fluoxetine versus sertraline and paroxetine in major depression: Tolerability and efficacy in patients with low and high baseline insomnia. European Psychiatry. 13(S4). 269s–269s. 1 indexed citations
4.
Beasley, Charles M., et al.. (1998). The influence of pharmacotherapy on selfdirected and externally-directed aggression in schizophrenia. Schizophrenia Research. 29(1-2). 28–28. 26 indexed citations
5.
Rosenbaum, Jerrold F., et al.. (1998). Fluoxetine versus sertraline and paroxetine in major depression: Efficacy and tolerability in patients with high or low baseline insomnia. European Neuropsychopharmacology. 8. S152–S152. 1 indexed citations
6.
Wernicke, Joachim, et al.. (1997). Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior.. PubMed. 6(1). 31–9. 15 indexed citations
7.
Sayler, Mary E., J. Street, J C Bosomworth, Janet H. Potvin, & James G. Kotsanos. (1995). Analysis of Mortality in Pergolide-Treated Patients with Parkinson's Disease. Neuroepidemiology. 15(1). 26–32. 2 indexed citations
8.
Goldstein, D., Alvin H. Rampey, Paul Roback, et al.. (1995). Efficacy and Safety of Long‐Term Fluoxetine Treatment of Obesity ‐ Maximizing Success. Obesity Research. 3(S4). 481S–490S. 44 indexed citations
9.
10.
Tollefson, Gary D., et al.. (1994). Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.. PubMed. 55(2). 50–9. 113 indexed citations
11.
Tollefson, Gary D., et al.. (1994). Is Baseline Agitation a Relative Contraindication for a Selective Serotonin Reuptake Inhibitor. Journal of Clinical Psychopharmacology. 14(6). 385???391–385???391. 43 indexed citations
12.
Beasley, Charles M., Mary E. Sayler, & Janet H. Potvin. (1993). Fluoxetine versus amitriptyline in the treatment of major depression. International Clinical Psychopharmacology. 8(3). 143–150. 27 indexed citations
13.
Pande, Anupam & Mary E. Sayler. (1993). Severity of depression and response to fluoxetine. International Clinical Psychopharmacology. 8(4). 243–246. 40 indexed citations
14.
Pande, Arindam & Mary E. Sayler. (1993). Adverse events and treatment discontinuations in fluoxetine clinical trials. International Clinical Psychopharmacology. 8(4). 267–270. 37 indexed citations
15.
Bowden, Charles L., Alan F. Schatzberg, Alan Rosenbaum, et al.. (1993). Fluoxetine and Desipramine in Major Depressive Disorder. Journal of Clinical Psychopharmacology. 13(5). 305???311–305???311. 56 indexed citations
16.
Beasley, Charles M. & Mary E. Sayler. (1992). FLUOXETINE: ACTIVATING AND SEDATING EFFECTS AT MULTIPLE FIXED DOSES. Clinical Neuropharmacology. 15. 325B–325B. 4 indexed citations
17.
Beasley, Charles M., Bruce E. Dornseif, J C Bosomworth, et al.. (1992). Fluoxetine and Suicide. International Clinical Psychopharmacology. 6. 35–57. 9 indexed citations
18.
Beasley, Charles M., et al.. (1992). Fluoxetine. Journal of Clinical Psychopharmacology. 12(5). 328???333–328???333. 45 indexed citations
19.
Beasley, Charles M., Mary E. Sayler, J C Bosomworth, & J. F. Wernicke. (1991). High-Dose Fluoxetine. Journal of Clinical Psychopharmacology. 11(3). 166???174–166???174. 40 indexed citations
20.
Beasley, Charles M., et al.. (1990). Fluoxetine in tricyclic refractory major depressive disorder. Journal of Affective Disorders. 20(3). 193–200. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J C Bosomworth Breakdown of academic impact, for papers by Ward T. Smith Breakdown of academic impact, for papers by William F. Boyer Breakdown of academic impact, for papers by Jay B. Cohn Breakdown of academic impact, for papers by Charles S. Wilcox Breakdown of academic impact, for papers by J.D. Guelfi Breakdown of academic impact, for papers by M. Fava Breakdown of academic impact, for papers by Ole Lemming Breakdown of academic impact, for papers by E Tricamo Breakdown of academic impact, for papers by Joseph Deltito
Rankless by CCL
2026